Deconstructing media coverage of trastuzumab (Herceptin): An analysis of national newspaper coverage

Journal of the Royal Society of Medicine

Volumn 101, Issue 3, 2008, Pages 125-132

  Wilson, Paul M ^a   Booth, Alison M ^a   Eastwood, Alison ^a   Watt, Ian S ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER STAGING; DATA BASE; DRUG COST; HUMAN; LICENCE; LICENSING; MEDICAL INFORMATION; MEDICAL LITERATURE; RETROSPECTIVE STUDY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 42449149551     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2007.070115     Document Type: Article

References (26)

1. Grilli R, Ramsay C, Minozzi S. Mass media interventions: effects on health services utilisation. Cochrane Database of Systematic Reviews 2002;1 . CD000389. DOI 10.1002/14651858.CD000389
2. Herceptin and early breast cancer: a moment for caution. Lancet 2005;366:1673
3. Ferner R, McDowell S. How NICE may be outflanked. BMJ 2006;332:1268-71
4. Raffle A. Lasting damage from the trastuzumab storm. BMJ 2006;333:761
5. Barrett A, Roques T, Small M, Smith R. How much will Herceptin really cost? BMJ 2006;333:1118-20
6. Keidan J. Sucked into the Herceptin maelstrom. BMJ 2007;334:18
7. National Institute for Health and Clinical Excellence. NICE to issue faster drugs guidance for the NHS. November 3. London: MCE; 2005. (Press Release)
8. Rogers R (on the application of) v Swindon NHS Primary Care Trust & Anor [2006]. EWHC 171 (Admin). England and Wales High Court (Administrative Court) 15 February 2006
9. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
10. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science 1989;244:707-12
11. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659-72
12. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM 2005;353:1673-84
13. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of earlystage HER2-positive breast cancer. August London: NICE; 2006. NICE Technology Appraisal Guidance 107
14. Roche. Roche files Herceptin for early-stage HER2-positive breast cancer with European Authorities. February 17. Basel: Roche; 2006. (Press Release)
15. Entwistle V. Reporting research in medical journals and newspapers. BMJ 1995;310:920-3
16. Wilkie T. Sources in science: who can we trust? Lancet 1996;347:1308-11
17. Entwistle V, Watt I, Johnson F. The case of Norplant as an example of media coverage over the life of a new health technology. Lancet 2000;355:1633-6
18. Cassels A, Hughes M, Cole C, Mintzes B, Lexchin J, McCormack J. Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. CMAJ 2003;168:1133-7
19. European Medicines Agency. European Medicines Agency statement on Herceptin. September 22. London: EMEA; 2005. (Press Release)
20. Boseley S. Wonder drug - or just a marketing triumph? The Guardian 2006; March 29.G2:6-9
21. Funding of patients' groups. The Lancet 2006;368:2
22. Gilbody S, Wilson P, Watt I. The benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care 2005;14:246-50
23. Laurance J. Medical breakthrough? No, just a marketing wheeze. The Independent on Sunday 2006; March 19
24. Moynihan R, Bero L, Ross-Degnan D, et al. Coverage by the news media of the benefits and risks of medications. NEJM 2000;342: 1645-50
25. Schwitzer G. How the media left the evidence out in the cold. BMJ 2003;326:1403-4
26. Schwartz L, Woloshin S. The media matter: a call for straightforward medical reporting. Ann Intern Med 2004;140:226-8